Eupraxia Pharmaceuticals Announces New Positive Data From RESOLVE Phase 1B/2A Trial Of EP-104GI For Treatment Of Eosinophilic Esophagitis
United States James Helliwell Eupraxia Diffusphere Eupraxia Pharmaceuticals Inc American Gastroenterological Association Chief Executive Officer
Source: menafn.com